EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study

Ruben P A van Eijk iD, Leonard H van den Berg iD, Kit C B Roes iD, Lu Tian iD, Tze L Lai, Lorene M Nelson iD, Chenyu Li, Anna Scowcroft iD, Jesus Garcia-Segovia, Ying Lu iD

Clinical Pharmacology & Therapeutics · 2023-10 · 114 (4) · 883-892

DOI: 10.1002/cpt.2994 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 19.07.2023. Verfasst von Ruben P A van Eijk und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Data Science and Centre for Innovative Study Design, School of Medicine, Stanford University, Stanford, California, USA. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hybrid designs with both randomized arms and an external control cohort preserve key features of randomization and utilize external information to augment clinical trials. In this study, we propose to leverage high‐quality, patient‐level concurrent registries to enhance clinical trials and illustrate the impact on trial design for amyotrophic lateral sclerosis. The proposed methodology was evaluated in a randomized, placebo‐controlled clinical trial. We used patient‐level information from a well‐defined, population‐based registry, that was running parallel to the randomized clinical trial, to identify concurrently nonparticipating, eligible patients who could be matched with trial participants, and integrate them into the statistical analysis. We assessed the impact of the addition of the external controls on the treatment effect estimate, precision, and time to reach a conclusion. During the runtime of the trial, a total of 1,141 registry patients were alive; 473 (41.5%) of them fulfilled the eligibility criteria and 133 (11.7%) were enrolled in the study. A matched control population could be identified among the nonparticipating patients. Augmenting the randomized controls with matched external controls could have avoided unnecessary randomization of 17 patients (−12.8%) as well as reducing the study duration from 30.1 months to 22.6 months (−25.0%). Matching eligible external controls from a different calendar period led to bias in the treatment effect estimate. Hybrid trial designs utilizing a concurrent registry with rigorous matching can minimize bias due to a mismatch in calendar time and differences in standard of care, and may accelerate the development of new treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisHumansFeasibility StudiesResearch Design

Autor:innen und Institutionen

  • Department of Biomedical Data Science and Centre for Innovative Study Design, School of Medicine, Stanford University, Stanford, California, USA.
  • Department of Neurology, UMC Utrecht Brain Centre, University Medical Centre Utrecht, Utrecht, The Netherlands.
  • Section Biostatistics, Department of Health Evidence, Radboud Medical Centre, Nijmegen, The Netherlands.
  • Department of Epidemiology and Population Health, School of Medicine, Stanford University, Stanford, California, USA.
  • UCB Pharma, Brussels, Belgium.

ORCID-Profile: Ruben P A van Eijk, Leonard H van den Berg, Kit C B Roes, Lu Tian, Lorene M Nelson, Anna Scowcroft, Ying Lu

Zitieren

APA

van Eijk, R. P. A., van den Berg, L. H., Roes, K. C. B., Tian, L., Lai, T. L., Nelson, L. M., Li, C., Scowcroft, A., Garcia-Segovia, J., & Lu, Y. (2023). Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study. Clinical Pharmacology & Therapeutics, 114(4), 883-892. https://doi.org/10.1002/cpt.2994

Vancouver

van Eijk RPA, van den Berg LH, Roes KCB, Tian L, Lai TL, Nelson LM, et al. Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study. Clinical Pharmacology & Therapeutics. 2023;114(4):883-892. doi:10.1002/cpt.2994

BibTeX
@article{vanEijk2023,
  author = {van Eijk, Ruben P A and van den Berg, Leonard H and Roes, Kit C B and Tian, Lu and Lai, Tze L and Nelson, Lorene M and Li, Chenyu and Scowcroft, Anna and Garcia-Segovia, Jesus and Lu, Ying},
  title = {Hybrid Controlled Clinical Trials Using Concurrent Registries in Amyotrophic Lateral Sclerosis: A Feasibility Study},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2023},
  volume = {114},
  number = {4},
  pages = {883--892},
  doi = {10.1002/cpt.2994}
}
Kostenlos starten →